dacarbazine + fluorouracil + semustine + vincristine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: - **Dacarbazine** (DTIC): an alkylating agent that works as an antineoplastic by methylating guanine in DNA, leading to inhibition of DNA synthesis and function. - **Fluorouracil** (5-FU): a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. - **Semustine** (MeCCNU): a nitrosourea alkylating agent that cross-links DNA and RNA, inhibiting their function. - **Vincristine** (VCR): a vinca alkaloid that binds tubulin and inhibits microtubule formation, arresting cell division at metaphase. This combination has been studied in phase III clinical trials for advanced colorectal cancer. The rationale for combining these drugs is to target cancer cells through multiple mechanisms—DNA damage/alkylation, inhibition of nucleotide synthesis, and disruption of mitosis—to maximize cytotoxicity and minimize resistance. This regimen does not have a unique brand or code name but is referenced in the literature as the combination of its components[1][5].

Other names

dacarbazine + 5-fluorouracil + semustine + vincristineDTIC + 5-FU + MeCCNU + VCR